What is Cognition Therapeutics Financial Strength?
Cognition Therapeutics has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Cognition Therapeutics did not have earnings to cover the interest expense.
As of today, Cognition Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison of Cognition Therapeutics's Financial Strength
For the Biotechnology subindustry, Cognition Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cognition Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Cognition Therapeutics's Financial Strength falls into.
Cognition Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Cognition Therapeutics's Interest Expense for the
months ended in Mar. 2024 was $-0.01 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-9.19 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.49 Mil.
Cognition Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is
| Cognition Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Cognition Therapeutics's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Cognition Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cognition Therapeutics (Cognition Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
2500 Westchester Avenue, Purchase, NY, USA, 10577
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Executives
| John Brendan Doyle |
officer: Chief Financial Officer |
C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494 |
| Lisa Ricciardi |
director, officer: CEO & President |
C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
| Anthony Caggiano |
officer: Chief Medical Officer |
C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
| Ellen B Richstone |
director |
C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886 |
| Fletcher Aaron G.l. |
director |
40 GUEST STREET, BOSTON MA 02135 |
| Leslie W. Kreis |
director, 10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Equity Partners Iii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Memory Spv Ii, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund Iii Nt, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii Qp, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Equity Partners Ii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Peggy Wallace |
director |
C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577 |
| Bios Fund Ii Nt, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund Ii Qp, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
Cognition Therapeutics (Cognition Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CGTX has been successfully added to your